A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer

Keyphrases

• Head-and-neck Cancer 100%
• Phase II Study 100%
• Erlotinib 100%
• Concurrent Radiation 100%
• Intra-arterial Cisplatin 100%
• Overall Survival 20%
• Survival Outcomes 20%
• Anti-EGFR 20%
• Treatment Duration 20%
• Chemotherapy 20%
• Radiotherapy 20%
• Total Dose 20%
• Serious Adverse Events 20%
• Primary Tumor 20%
• Improved Survival 20%
• Disease Rate 20%
• Distant Metastasis 20%
• Chemoradiation 20%
• Maintenance Therapy 20%
• Locally Advanced 20%
• Anti-epidermal Growth Factor Receptor Therapy 20%
• Biologic Therapy 20%
• Persistent Disease 20%
• Oral Dosing 20%
• Metastatic Rate 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Cisplatin 100%
• Head and Neck Cancer 100%
• Erlotinib 100%
• Epidermal Growth Factor Receptor 40%
• Chemotherapy 20%
• Chemoradiation Therapy 20%
• Adverse Event 20%
• Overall Survival 20%
• Disease 20%
• Primary Tumor 20%